The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France

INTRODUCTION: Dulaglutide is a novel onceweekly administered glucagon-like peptide 1 receptor agonist (GLP-1 RA) for the management of type 2 diabetes mellitus (T2DM). The objective of this analysis was to estimate the cost-effectiveness of dulaglutide 1.5 mg versus exenatide QW for the management o...

Descripción completa

Detalles Bibliográficos
Autores principales: Basson, Mickael, Ntais, Dionysios, Ayyub, Ruba, Wright, Donna, Lowin, Julia, Chartier, Florence, Roze, Stéphane, Norrbacka, Kirsi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801216/
https://www.ncbi.nlm.nih.gov/pubmed/29134607
http://dx.doi.org/10.1007/s13300-017-0321-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801216/
https://www.ncbi.nlm.nih.gov/pubmed/29134607
http://dx.doi.org/10.1007/s13300-017-0321-0

Ejemplares similares